Stock Events

Stock Events

Vaccitech 

$5.00
11
+$0.51+11.36% Monday 22:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
186.48M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.62
-0.55
-0.47
-0.4
Expected EPS
-0.54
Actual EPS
-0.4

Financials

69.37%Profit Margin
Profitable
2020
2021
2022
38.25MRevenue
26.53MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in the same therapeutic areas as Barinthus Biotherapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening diseases, overlapping with Barinthus Biotherapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions, similar to Barinthus Biotherapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a global biotechnology company that develops innovative human therapeutics, with a product portfolio that competes with Barinthus Biotherapeutics in several key areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, autoimmune disorders, and rare diseases, competing with Barinthus Biotherapeutics in the biopharmaceutical sector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics, a novel technology that competes with Barinthus Biotherapeutics' innovative approaches to drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on rare genetic diseases, competing with Barinthus Biotherapeutics in targeting niche and underserved medical conditions.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad range of products that compete across several of Barinthus Biotherapeutics' key strategic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical corporation with a diverse portfolio, including areas that overlap with the therapeutic focus of Barinthus Biotherapeutics.

About

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Show more...
CEO
Employees
49
Country
United States
ISIN
US91864C1071
WKN
000A3CN5Q

Listings

F
DE
2AB.F
STU
DE
2AB.STU
MU
DE
2AB.MU
XNAS
US
BRNS

0 Comments

Share your thoughts

FAQ

What is Vaccitech stock price today?▼
The current price of VACC is $5.00 USD — it has increased by +11.36% in the past 24 hours. Watch Vaccitech stock price performance more closely on the chart.
What is Vaccitech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vaccitech stocks are traded under the ticker VACC.
What is Vaccitech market cap?▼
Today Vaccitech has the market capitalization of 186.48M
What were Vaccitech earnings last quarter?▼
VACC earnings for the last quarter are 0 USD per share, whereas the estimation was -0.57 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaccitech revenue for the last year?▼
Vaccitech revenue for the last year amounts to 38.25M USD.
What is Vaccitech net income for the last year?▼
VACC net income for the last year is 26.53M USD.
How many employees does Vaccitech have?▼
As of September 04, 2026, the company has 49 employees.
In which sector is Vaccitech located?▼
Vaccitech operates in the Technology sector.
When did Vaccitech complete a stock split?▼
Vaccitech has not had any recent stock splits.